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See related research by Evans et al. http://www.breast-cancer-research.com/content/16/5/442In May 2013 the actress Angelina Jolie informed the
press that she had undergone bilateral risk-reducing
mastectomy (BRRM) because she carried a maternally
inherited pathogenic BRCA1 mutation. This decision
created huge publicity worldwide [1] and led to enor-
mous interest in hereditary breast cancer/genetic testing.
Here we comment on our recently published research
article in Breast Cancer Research and provide more re-
cent observations. This reported a 2.5-fold increase in
referrals of UK women with family histories of breast
cancer 3–4 months following Ms Jolie’s revelation [1].
We also highlighted increased interest in BRRM; how-
ever, as it takes 9–12 months from initial BRRM en-
quiries to the operative procedure, we can now report a
similar 2.5-fold increase in uptake of BRRM in the 6–24
months following this.
The Genesis Prevention Centre Family History clinic
(GPCFHC) covers an extended population of around 5
million. Although the main impact of the Angelina effect
was from June to November 2013, this trend continued
through 2014 with increased referrals from 201 in Janu-
ary–June 2012 to 388 (odds ratio (OR) 1.93) in January
to June 2014 and rising by 366 (OR 2.09) for the last
6 months to give a total of 754 for 2014. Women attend-
ing for risk assessment and discussions concerning
BRRM, unprompted, still mention the effects of Ange-
lina Jolie on their attendance anecdotally to clinic* Correspondence: gareth.evans@cmft.nhs.uk
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publicly in their pre-surgery consultations with the clin-
ical psychologist in 2015. A clear upward trend in BRRM
can be seen starting around 6 months after the news an-
nouncement in May 2013 (Fig. 1). The number of high-
risk women without BRCA1/2 mutations undergoing
BRRM (n = 12; 18 months from January 2011) rose to 52
(18 months from January 2014). The number in muta-
tion carriers rose from 17 to 31. The overall combined
rise from 29 BRRMs to 83 was significant (high-risk
women at GPCFHC, n = 2012; chi-square p < 0.0001).
Again BRRM numbers annually had been stable at
around 20 (2000–2011). We speculate that the BRRM
rate rise was probably contributed by the ‘Angelina ef-
fect’. This effect was seen not just in carriers of BRCA1/
BRCA2, but was actually greater in those without muta-
tions. Nonetheless, 23/31(74 %) BRRMs in mutation car-
riers were in women >18 months after testing positive,
indicating a delay in decision-making, whereas prior to
2013 the majority of women had BRRM within
18 months of testing positive [2]. There was a slight rise
in the number of unaffected women newly testing posi-
tive for BRCA1/2 in Manchester from 81 to 116 in the
2 years before and the 2 years after Angelina’s announce-
ment, although this could have been impacted by new
National Institute for Health and Care Excellence
(NICE) guidelines announced in June 2013 [3]. This re-
search was exempt from ethical approval as this is an
audit of clinical service and does not contain identifiable
data.
The present audit of further new referrals and BRRM
rates indicates that the Angelina effect has been prolonged
and has impacted on increased referral and BRRM rates.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Fig. 1 Number of BRRMs carried out at Wythenshawe and Christie
hospitals per 6-month period from 2011 and proportion with
mutations in high-risk genes. a January–June, b July–December,
red proportion with BRCA1/2/TP53 mutations, BRRM bilateral
risk-reducing mastectomy
Evans et al. Breast Cancer Research  (2015) 17:143 Page 2 of 2It would be interesting to see results from centres world-
wide. Plans to offer breast cancer risk assessment on a
population basis could further affect uptake of BRRM [4].
It is also possible that similar effects will be seen on the
already increasing rates of contralateral mastectomy in
women with breast cancer [5].
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